A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2022-11-02
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-20 (study day 284); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-23 (study day 409); relationship: not assessed
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-04-28 (study day 536); relationship: not assessed
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-10-08 (study day 699); relationship: not assessed
Data queries
No data queries.